Solventum detailed its 2025-2028 growth strategy, reaffirmed its 2025 guidance, and reported Q4 earnings that topped expectations with strong sales and EPS.
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how surgical equipment & consumables - diversified stocks fared in Q4, starting with Solventum (NYSE:SOLV).
As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the surgical equipment & consumables - diversified industry, including BD (NYSE:BDX) and its peers.
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at CONMED (NYSE:CNMD) and the best and worst performers in the surgical equipment & consumables - diversified industry.
Shares of healthcare solutions provider Solventum (NYSE:SOLV)
fell 6.5% in the morning session after the company reported weak fourth quarter results: its full-year EPS guidance missed. On the other hand, Solventum narrowly topped analysts' organic revenue expectations, with organic sales rising 2.3% year-on-year, led by growth in its MedSurg and Dental Solutions segments. Looking ahead, the company expects 1% to 2% organic revenue growth in 2025 but will update its guidance following the sale of its Purification & Filtration segment. Overall, we think this was a mixed quarter. The areas below expectations seem to be driving the move.
Stay informed about the performance of the S&P500 index one hour before the close of the markets on Friday. Uncover the top gainers and losers in today's session for valuable insights.
Healthcare solutions provider Solventum (NYSE:SOLV) reported revenue ahead of Wall Street’s expectations in Q4 CY2024, with sales up 1.9% year on year to $2.07 billion. Its non-GAAP profit of $1.41 per share was 7.8% above analysts’ consensus estimates.
Solventum shares are trading higher Tuesday after the company announced it will sell its purification and filtration business to Thermo Fisher for $4.1 billion in cash.
Thermo Fisher will acquire Solventum's Purification & Filtration business for $4.1 billion, expanding its bioproduction portfolio with expected long-term growth.
Solventum has had an impressive run over the past six months as its shares have beaten the S&P 500 by 15.9%. The stock now trades at $74.24, marking a 24.9% gain. This was partly due to its solid quarterly results, and the run-up might have investors contemplating their next move.
